secwatch.observer — SEC 8-K summary
======================================

Issuer:     NUVASIVE INC (—)
CIK:        0001142596
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001193125-23-227202
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NuVasive completes merger with Globus Medical, shareholders get 0.75 GMED shares
--------------------------------------------------------------------------------

- Merger closed Sep 1, 2023; NuVasive shareholders received 0.75 Globus Medical Class A shares per NUVA share.
- NuVasive common stock to be delisted from Nasdaq after Form 25 filed; reporting obligations to be suspended.
- CEO J. Christopher Barry and CFO Matthew Harbaugh depart; Daniel Scavilla named CEO, Keith Pfeil CFO of NuVasive.
- All prior directors cease; Scavilla and Pfeil become directors; charter and bylaws amended.
- Convertible notes and bond hedges amended; conversion rights now based on Globus Medical common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/d469541d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-227202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer